MED Valuation

Medifast Inc

Add to Watchlist

Advanced Chart

13.190

+0.36(2.806%)1D

Overview
Forecast
Valuation
Earnings

MED Relative Valuation

MED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MED is overvalued; if below, it's undervalued.

Get winning stock picks in minutes

Historical Valuation

Medifast Inc (MED) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.38 is considered Undervalued compared with the five-year average of 12.91. The fair price of Medifast Inc (MED) is between 18.57 to 51.27 according to relative valuation methord. Compared to the current price of 13.34 USD , Medifast Inc is Undervalued By 28.16%.

Relative Value

Fair Zone

18.57-51.27

Current Price：13.34

28.16%

Undervalued

-8.28

Trailing

Forward

1.48

EV/EBITDA

Medifast Inc. (MED) has a current EV/EBITDA of 1.48. The 5-year average EV/EBITDA is 7.53. The thresholds are as follows: Strongly Undervalued below 0.19, Undervalued between 0.19 and 3.86, Fairly Valued between 11.20 and 3.86, Overvalued between 11.20 and 14.87, and Strongly Overvalued above 14.87. The current Forward EV/EBITDA of 1.48 falls within the Undervalued range.

0.68

EV/EBIT

Medifast Inc. (MED) has a current EV/EBIT of 0.68. The 5-year average EV/EBIT is 8.64. The thresholds are as follows: Strongly Undervalued below -17.28, Undervalued between -17.28 and -4.32, Fairly Valued between 21.61 and -4.32, Overvalued between 21.61 and 34.57, and Strongly Overvalued above 34.57. The current Forward EV/EBIT of 0.68 falls within the Historic Trend Line -Fairly Valued range.

0.38

Medifast Inc. (MED) has a current PS of 0.38. The 5-year average PS is 1.07. The thresholds are as follows: Strongly Undervalued below -0.09, Undervalued between -0.09 and 0.49, Fairly Valued between 1.66 and 0.49, Overvalued between 1.66 and 2.24, and Strongly Overvalued above 2.24. The current Forward PS of 0.38 falls within the Undervalued range.

0.00

P/OCF

Medifast Inc. (MED) has a current P/OCF of 0.00. The 5-year average P/OCF is 10.92. The thresholds are as follows: Strongly Undervalued below 0.39, Undervalued between 0.39 and 5.65, Fairly Valued between 16.18 and 5.65, Overvalued between 16.18 and 21.45, and Strongly Overvalued above 21.45. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

-13.31

P/FCF

Medifast Inc. (MED) has a current P/FCF of -13.31. The 5-year average P/FCF is 19.47. The thresholds are as follows: Strongly Undervalued below -16.78, Undervalued between -16.78 and 1.34, Fairly Valued between 37.59 and 1.34, Overvalued between 37.59 and 55.71, and Strongly Overvalued above 55.71. The current Forward P/FCF of -13.31 falls within the Undervalued range.

Medifast Inc (MED) has a current Price-to-Book (P/B) ratio of 0.61. Compared to its 3-year average P/B ratio of 3.69 , the current P/B ratio is approximately -83.49% higher. Relative to its 5-year average P/B ratio of 7.93, the current P/B ratio is about -92.32% higher. Medifast Inc (MED) has a Forward Free Cash Flow (FCF) yield of approximately -1.84%. Compared to its 3-year average FCF yield of 18.79%, the current FCF yield is approximately -109.77% lower. Relative to its 5-year average FCF yield of 13.01% , the current FCF yield is about -114.11% lower.

0.61

P/B

Median3y

3.69

Median5y

7.93

-1.84

FCF Yield

Median3y

18.79

Median5y

13.01

Get winning stock picks in minutes

Competitors Valuation Multiple

The average P/S ratio for MED's competitors is 0.63, providing a benchmark for relative valuation. Medifast Inc Corp (MED) exhibits a P/S ratio of 0.38, which is -39.97% above the industry average. Given its robust revenue growth of -37.38%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Roma Green Finance Ltd

Loss

178.10M

STG.N

Sunlands Technology Group

Resources Connection Inc

Loss

-5.98%

151.70M

Performance Decomposition

Market capitalization of MED decreased by 27.92% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 15.07 to 38.89.

The secondary factor is the Revenue Growth, contributed -37.38%to the performance.

Overall, the performance of MED in the past 1 year is driven by P/E Change. Which is more unsustainable.

-37.38%

168.56M → 105.56M

Revenue Growth

-148.55%

-4.84 → 2.35

Margin Expansion

158.01%

15.07 → 38.89

P/E Change

-27.92%